Simbionix Appoints Director of Newly Established Regulatory Affairs Department

By Simbionix Usa Corporation, PRNE
Monday, April 4, 2011

CLEVELAND, April 5, 2011 - Simbionix USA Corporation, the world's leading provider of medical
education and simulation training products for medical professionals and the
healthcare industry, is pleased to announce the appointment of Dr. Yael
to Director of the newly established Regulatory Affairs Department.
Simbionix has leveraged its leading position in the healthcare training and
education market to expand its activities into the clinical market, having
recently received market clearance for the PROcedure Rehearsal Studio(TM)
software, the next generation in "patient specific simulation".

With a PhD in Biology and twenty years research experience in leading
universities in the USA and Israel, Dr. Friedman has been with Simbionix for
the past ten years as Chief Scientist for Medical Projects. Dr. Friedman's
deep understanding of the potential and requirements of medical simulation
has led to a long track record of successful activities in the simulation
market. By working closely with key opinion leaders, medical societies, and
professional associations to create meaningful, effective and scientifically
validated simulation products, her efforts have resulted in the publication
of some 130 validation papers on Simbionix products, demonstrating and
validating their value in medical education. For the past two years Dr.
Friedman has also taken the lead in the company's regulatory activities,
successfully navigating the process of obtaining an FDA 510(k) clearance for
Simbionix's new and exciting PROcedure Rehearsal Studio(TM) software.

"Yael represents the core values of Simbionix, namely creating innovative
products that improve patient care and outcomes while responding to the
market's ever increasing simulation needs," said Gary Zamler, CEO of
Simbionix. "We are very pleased we are able to bring our innovative
simulation technologies to the clinical market and have established the
Regulatory Affairs Department to better serve the market, by accelerating
future PROcedure Rehearsal Studio(TM) products under development. To the best
of our knowledge Simbionix is the only simulation company to be granted FDA
510(k) clearance for a simulation technique. We are building on our
successful experience in the healthcare training and education market and
expanding it to create simulation based products for the clinical market as
well. Yael is the ideal person to lead our global Regulatory Affairs
activities as we expand into the clinical market."

About Simbionix USA Corporation

Simbionix is the world's leading provider of simulation and training
products for medical professionals and the healthcare industry. Founded in
1997, the company is committed to delivering high quality products, advancing
clinical performance and optimizing procedural outcomes. Simbionix cooperates
with physicians on a regular basis to produce the most reliable and effective
training and supporting systems.

For more information on Simbionix, visit

Contact: +1-216-229-2040 ext. 128

Contact: rebecca at +1-216-229-2040 ext. 128

will not be displayed